More recently, increased interest in JAKi strategies arose for the need of potential treatments for COVID-19, which is implicated in the activation of CD4+ and CD8+ positive T cells, NK cells and monocytes that cooperate with cytokine storm generated by SARS-COV2 (46, 47). This evidence concerns the gene CD8A and COVID-19.